Stelara

• Brands Stelara
• Product Code: Stelara

• Stelara is a fully human immunoglobulin G1κ monoclonal antibody that binds specifically to the p40 subunit shared by IL-12 and IL-23, preventing their interaction with the IL-12Rβ1 receptor. This action inhibits downstream inflammatory pathways—particularly Th1 and Th17 cytokine responses—thereby reducing pathological inflammation.

  Indications

  Stelara is indicated for:

  • Plaque psoriasis in adults (and in some regions, children);

  • Psoriatic arthritis, alone or with methotrexate;

  • Moderately to severely active Crohn’s disease;

  • Moderately to severely active ulcerative colitis.
    For patients with Crohn’s or ulcerative colitis, it is used when they have failed conventional or biologic therapies.

  Administration & Dosing

  • Psoriasis / Psoriatic arthritis:

    • Adults ≤ 100 kg: 45 mg SC at Week 0, Week 4, then every 12 weeks.

    • Adults > 100 kg: 90 mg on same schedule. Pediatric dosing is weight-based as well

  • Crohn’s disease / Ulcerative colitis:

    • Initial IV infusion (weight-based, ~6 mg/kg), followed by 90 mg SC at Week 8, then every 8 or 12 weeks depending on response and clinician judgment.

  Onset & Outcomes

  • For ulcerative colitis, many patients experience symptom relief by Week 8; about 40% maintain remission at 1 year, with evidence of reduced intestinal inflammation.

  Side Effects & Precautions

  Common adverse events include:

  • Respiratory infections, headache, fatigue, injection site reactions, diarrhea (especially in IBD).
    Less common but serious risks include:

  • Increased susceptibility to infections, potential reactivation of latent tuberculosis, hypersensitivity reactions, and possible elevation of cancer risks (e.g., skin cancer). Live vaccines should generally be avoided during treatment.

• Availability: In Stock

• American Diabetes Association

• Diabetes Disaster_Response Coalition storing insulin

• FDA Approved Prescription